



Sharm Derma *Summer* Academy

Basics to Practical Dermatology and Aesthetics

19th August
21st 2021
Steigenberger Hotel
El Lessan Ras El Bar

SHARM DERMA ACADEMY BOARD



SHARM DERMA ACADEMY SPEAKERS



SHARM DERMA ACADEMY SPEAKERS



IBRAHIM FOUDA



AHMED AFIFI



YASMIN ALATTAR



SHERIF REFAAT ISMAIL



MOSTAFA GHONEIM



AHMED AL ATTAR



MOHAMED MONGY



SARA MOHEY EL DIN

MEDICAL SPONSORING COMPANIES

Organizing committee gratefully acknowledges the support and contributions of the following companies, without whom this congress would not be possible.

Diamond



Paltinum

ANIVAGENE™**BIODERMA**
LABORATOIRE DERMATOLOGIQUE**ISISPHARMA**
DERMATOLOGIE**DUCRAY**
LABORATOIRES DERMATOLOGIQUES

Daily life-changing care

SVR
LABORATOIRE DERMATOLOGIQUE**ACM**
LABORATOIRE
DERMATOLOGIQUE
ECRINAL®**Foltène®**
• P H A R M A •EAU THERMALE
Avène**URIAGE**
EAU THERMALE**SANDOZ** A Novartis
Division**UTOPIA**
THE LIFE YOU DESERVE**Levohistam**
3rd Generation Antihistamine
Itrafungex
Broad spectrum antifungal

Gold



Johnson & Johnson



MELADEEP

RENÉE



DERCOS

VICHY
LABORATOIRES



ME[®]
LINE






Silver




Bronze



THURSDAY 19/8/2021

08:00-10:00	Registration		
	Introduction	Assem Farag	
10:30-11:45 Aesthetic Tools in your clinic			
Chairpersons May Elsamahy Rehab Hegazy Rania Moneir	Botulinum Toxin in Hyperhidrosis	Rania Monier	
	The Power of Microneedling	Yasmine Alattar	
	What is beyond PRP in Dermatology? 15 min	Shady Mahmoud	
	Peeling masks: practical tips from practice Meladeep Mask: How to Customize it for all needs 15 min	Nevine Dorgham	  
	Meline: What you need to know for best results 15 min		
11:45-12:30 Diagnostic Dermoscopy Made Simple			
Chairpersons Hoda Monieb Manal Bosseila	Alphabet of Dermoscopy	Heba Gawdat Ahmed Afifi	
	Dermatofibroma: the many faces Solar lentigo, Seborrheic keratosis : Beware of Imitators	Hoda Monieb	
	Cutting the edge in the Diagnosis of Psoriasis, Bowen's BCC	Manal Bosseila	

12:30-01:30Psoriasis			
Chairpersons Assem Farag Mahmoud Abdallah	Look within PsO: Look better Introduction	Assem Farag	
	Look within PsO: Move better 20 min	Mahmoud Abdallah	
	Look within PsO: Feel better 20 min	Amin Sharobim	
	Unraveling Chronic Spontaneous Urticaria 20 min	Rehab Hegazy Amin Sharobim Real Experience with CSU	
01:30-02:00Coffee Break			
02:00-03:00Antiaging tools			
Chairpersons Rehab Hegazy Nevine Dorgham	Upper face	Amin Sharobim	
	Lower face	Mohamed Hussein	
	Microbotox	Rehab Hegazy	
Moderator Rehab Hegazy	Skin Boosters: Anti-aging Protocol 15 min	Shady Mahmoud	
03:00-04:00Atopic Dermatitis			
Chairpersons Mahmoud Abdallah Rehab Hegazy	Atopic Dermatitis Pathophysiology & Disease Burden 30 min	Mahmoud Abdallah	  DUPIXENT® (dupilumab) CONTINUOUS CONTROL
	Clinical Approaches to Atopic Dermatitis 30 min	Rehab Hegazy	
04:00-04:30Supplements in Dermatology: All you need to know			
Chairpersons Assem Faarg Hoda Moneib May El Samahy Marwa Abdallah	Nutrition for Dermatologists 30 min	Amin Sharobim Hany Abouel Wafa	

04:30-5:00				Biosimilars introduction to psoriasis patients			
Chairpersons Mahira El Sayed May El Samahy Mahmoud Abdallah Rehab Hegazy		Value of Biosimilars introduction to Psoriasis patients 30 min		Amin Sharobim			
05:00-05:30 Lunch Break							
05:30-06:30 Acne Challenging Cases							
Chairpersons Assem Farag May El Samahy Marwa Abdallah		Maskne: The new ACNE		Sara Mohey Eldin			
		Guidelines in Acne treatmenta 15 min		Marwa Abdallah			
		Acne Mimics		May El Samahy			
		Dilated pores		Hanan Morsy			
06:30-07:00 Isotretinoin (Sunpharma) Contest							
Chairpersons Assem Farag Mohamed El-Kahalwany		Isotretinoion: off label uses 10 min		Mohamed El-Khalawany		 	
		Isotretinoin: The State of the Art Treatment for Acne 10 min		Hany Abouel Wafa			
		Isotretionin Golden Contest 10 min		Shady Mahmoud			
07:00-07:30 Clinical Cases Competition							
Chairpersons Ashraf Hassan Mohamed Khaled		Clinical Cases		Manar Aly Aya Sabry Amr Shabka Haroun Roshdy			
07:30-08:00 Teoxane Workshop							
		Multi-layering Technique		Amin sharobim			

FRIDAY 20/8/2021

09:00-10:00

Aesthetic tools in your clinic

Chairpersons
Rehab Hegazy
Amin Sharobim

Midface

Jawline and chin

Lip

Periorbital

Amin Sharobim
Mohamed Hussien
Mohamed Mongy
Nevine Dorgham

10:00-11:00

Laser devices & Advices

Chairpersons
**Mohamed Saad
Hegazy**

 Best wavelength for
best hair removal
laser for best
candidate

Mohamed Mongy
Waleed ElBalat
Shady Mahmoud

 Nd:YAG for vascular
lesions

Waleed Elbalat

Laser End point

**Mohamed Saad
Hegazy**

 Fractional CO2 is
the hero in your
clinic

Shady Mahmoud

11:00-12:00

Psoriasis Management (Janssen)

Chairpersons
**Mohamed Saad
Hegazy**
Rehab Hegazy

 Psoriasis
management: how
to think










**Mohamed Saad
Hegazy
30 min**
**Rehab Hegazy
30 min**

 janssen Immunology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

 Tremfya™
 (guselkumab)

12:00-01:00

Gomaa prayer & Coffee break

01:00-02:00 Hair diseases: from trichoscopy to therapy			
Chairpersons Assem Farag Hoda Moneib	Trichoscopic clues in Diagnosing Diffuse Hair loss & Management Approach 30 min	Assem Farag Hoda Moneib	 
	Hair Photoprotection: What we need to know? 15 min	Heba Gawdat	
	Female Pattern hair loss: How to Diagnose? What's new in hair loss Treatment? 15 min	Hoda Monieb Engy seif Eleslam	 Daily life-changing care
02:00-03:00 The whole spectrum of pigmentation			
Chairpersons Assem Farag Marwa Abdallah Manal Bosseila Heba Gawdat	Vitilligo Mimics	Marwa Abdallah	
	Hyperpigmentation: Different Case Scenarios 15 min	Heba Gawdat	
	A closer look at Melasma and Photoprotection	Sherif Refaat Ismail	
	Novel means of Photoprotection 15 min	Ahmed AlAttar	
	More than one line of Rejuvenation 15 min	Ahmed Afifi	
03:00-03:30 Pruritis and Anti-pruritic Agents			
Chairperson Prof. Assem Farag Prof. Amany Nassar	Pruritis and Anti-pruritic Agents 30 min	Hany Abouel Wafa	 

03:30-04:30 How to Manage Recalcitrant Cases in Dermatology?

Chairpersons
Manar Sallam
Mohamed AlAzab
Yaser El-Gohary

Difficult to Treat
Warts : How to Deal

Manar Sallam

Rosacea: A therapeutic challenge

Ibrahim Fouda

Updates in Treatment of Keloid

Engy Seif Eleslam

Hirsutism: what's Beyond laser hair reduction?

Mostafa Ghoniem

04:30-05:00 Live Demonstration (Aptos Threads)

Non Surgical
Rhinoplasty
30 min

Amr Elnagary


05:00-06:00 Clinicopathological Correlation (5 cases Contest)

Chairpersons
Assem Farag

Mohamed El-Khalawany

Mohamed El-Banhawy

Mohamed Samir Abdel Aziz

George Tharwat Milad Dirias


06:00-06:30 Lunch break

08:30

Dinner



10:00
12:00

1st Procedural Dermatology Program
in Sharm Derma Academy

HALL B



Subcision | Chemical peel | Micro Needling
Interlesional | PRP



Skin clearance should stand the test of time



For superior skin clearance vs secukinumab and adalimumab

TREMFYA® achieved PASI 90 in:

- **84.5%** of patients at week 48, compared with **70%** on secukinumab ($P < 0.001$)¹
- **73.3%** of patients at week 16, compared with **49.7%** on adalimumab ($P < 0.001$) sustained out to week 48²

For long-lasting skin clearance that stands the test of time

TREMFYA® maintained PASI 90 out to 4 years in **82.2%** of patients³

For skin clearance with a generally well-tolerated safety profile*

TREMFYA® has no specific class effect warnings for candidiasis, Crohn's disease, demyelinating diseases or congestive heart failure^{†4}

Stand for lasting skin clearance with TREMFYA®³

PASI = Psoriasis Area and Severity Index

* The most common adverse drug reaction was upper respiratory infection

† Special warning and precautions for TREMFYA®: infections, tuberculosis, serious hypersensitivity reaction and immunisations (please refer to Summary of Product Characteristics for further details).

Tremfya™ 100 mg solution for injection in pre-filled pen **PRESCRIBING INFORMATION. ACTIVE INGREDIENT(S):** Guselkumab. Please refer to Summary of Product Characteristics (SmPC) before prescribing. **INDICATION(S):** Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. **DOSAGE & ADMINISTRATION:** For use under guidance/supervision of physician experienced in diagnosis and treatment of plaque psoriasis. Subcutaneous injection. Avoid areas showing psoriasis. **Adults:** 100 mg at weeks 0 and 4, followed by maintenance dose every 8 weeks. Consider discontinuation if no response after 16 weeks of treatment. **Children:** No data available in children/adolescents <18 years. **Elderly:** No dose adjustment required, limited information in subjects aged ≥ 65 years. **Renal & Hepatic impairment:** Not studied. **CONTRAINDICATIONS:** Serious hypersensitivity to active substance or excipients; clinically important, active infection. **SPECIAL WARNINGS & PRECAUTIONS: Infections:** Potential to increase risk. If signs/symptoms of clinically important chronic/acute infection occur, monitor closely and discontinue Tremfya until resolved. **Tuberculosis:** Evaluate patients for TB pre-treatment; monitor for signs/symptoms of active TB during and after treatment. Consider anti-TB therapy prior to Tremfya if past history of latent/active TB and adequate treatment course not confirmed. **Serious hypersensitivity reaction:** Includes anaphylaxis. Some serious hypersensitivity reactions occurred several days after treatment and included urticaria and dyspnoea. If occurs, discontinue Tremfya immediately and initiate appropriate therapy. **Immunisations:** Consider completing all appropriate immunisations prior to Tremfya. Do not use live vaccines concurrently with Tremfya; no data available; before live vaccination, withhold Tremfya for at least 12 weeks and resume at least 2 weeks after vaccination. **SIDE EFFECTS:** **Very common:** Upper respiratory infection. **Common:** Gastroenteritis, herpes simplex infections, tinea infections, headache, diarrhoea, urticaria, arthralgia, injection site reactions. **Other side effects:** hypersensitivity, anaphylaxis, rash. **Refer to SmPC for other side effects.** **LEGAL CATEGORY:** Prescription Only Medicine (POM). **PRESENTATIONS, PACK SIZES, MARKETING AUTHORISATION NUMBER(S):** Pre-filled pen, x1, EU/1/17/1234/002. **MARKETING AUTHORISATION HOLDER:** Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium. **FURTHER INFORMATION IS AVAILABLE FROM:** Janssen Sciences Ireland UC, Barnahely, Ringaskiddy, IRL - Co. Cork, P43 FA46. **Prescribing information last revised:** May 2020 (CHMP opinion).

Adverse events should be reported. ▼ This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product. Healthcare professionals are asked to report any suspected adverse events via: HPRA Pharmacovigilance Website: www.hpra.ie


Adverse events should also be reported to Janssen Sciences Ireland UC on 1800 709 122 or at dsafety@its.jnj.com.

© Janssen-Cilag Limited 2020

References: 1. Reich K et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE). The Lancet Available Online August 08, 2019. 2. Blauvelt A et al. J Am Acad Dermatol 2017; 76(3): 405-417. 3. Griffiths C.E.M. et al. Fall Clinical Dermatology Conference, October 17-20, 2019; Las Vegas, NV. 4. TREMFYA® Summary of Product Characteristics. Available at www.medicines.ie.

janssen  **Immunology**
PHARMACEUTICAL COMPANIES OF **Johnson & Johnson**

 **Tremfya**®▼
(guselkumab)



janssen  Immunology
PHARMACEUTICAL COMPANIES OF 



GIVE YOUR PATIENT
THE LOOK, FEEL AND MOVE



For full prescribing information, please contact:

Novartis Pharma S.A.E

3 El Sawah St., El Amria, Cairo, Egypt

P.O. Box 1893 - Code 11511

Tel: +202 22961000

Fax: +202 24505345

www.novartis.com.eg



 **Cosentyx[®]**
secukinumab

LOOK WITHIN




NOVARTIS

For full prescribing information, please contact:

Novartis Pharma S.A.E.
3 El Sawah St., El Amria, Cairo, Egypt
P.O. Box 1893 - Code 11511
Tel: +202 22661000
Fax: +202 24503345
www.novartis.com.eg

Xolair
omalizumab



701448/2

 **NOVARTIS**

For full prescribing information, please consult:
Novartis Pharma S.A.S.
18, Avenue de la République, 92000 Nanterre, France
01 69 00 00 00 - Fax 01 69 00 00 00
www.novartis.com

Xolair
omalizumab



704149/7

NOVARTIS

For full prescribing information please contact:
Novartis Pharma S.A.E
3 El Sawah St. El Amina, Cairo, Egypt
P.O. Box 1893 - Code 11511
Tel.: +202 22861000
Fax: +202 24505345
www.novartis.com.eg

NON-DROWSY



✓ **FASTER ONSET OF ACTION**

✓ **MORE POTENT**

In flare and wheal suppression than Desloratadine 5 mg¹

Telfast®

Fexofenadine HCl

SANOFI 

1- Nelson, H. et al. Fexofenadine HCl is Safe and Effective for Treatment of Chronic Idiopathic Urticaria. Annals of Allergy, Asthma & Immunology (2000), 84 (5), 517-522.



SHARED RESULTS

SHARED RELIEF

» First and only therapy that **specifically targets IL-4 and IL-13**, key drivers of persistent underlying Type 2 inflammation^{1,2}

» **Rapid and sustained improvement** in lesion extent and severity, pruritus intensity and quality-of-life measures^{1,3,4}

» Demonstrated **safety profile** across 52 weeks¹
— **No monitoring** for organ toxicities required¹
• Most common adverse reactions were injection site reactions, conjunctivitis, blepharitis, and oral herpes¹

VISIT [LOCAL WEBSITE PLACEHOLDER] TO LEARN MORE

DUPIXENT is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.

References: 1. DUPIXENT Summary of Product Characteristics. October 2018. 2. Gandhi NA et al. *Nature Rev Drug Disc* 2016; 15: 35–50. 3. Blauvelt A et al. *Lancet* 2017; 389: 2287–2303. 4. de Bruin-Weller M et al. Presentation at 27th EADV Congress; 2018; September 12–16; Paris, France.

API placeholder — safety warnings to also be included as per local regulatory guidance, i.e. for EU countries, please ensure to include the inverted black triangle at the first mention of the trade name / logo, and add the triangle text as a footnote.

SANOFI GENZYME 

REGENERON





© 2019 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. SAGLB.DUP.19.02.0144 03/2019

DUPIXENT[®] 
(dupilumab)
CONTINUOUS CONTROL

Organized by



Contact Us

-  16 Fathi Talaat Street-Sheraton Builds. - Cairo
-  +20 (2) 22666152 -22666156 - 01001634534
-  www.misr2000online.net
-  www.facebook.com/misr2000